Twist Bioscience Unveils Plasmid Preps to Fuel Nucleic-Acid Therapeutics Research
San Francisco, CA – December 4, 2025 — Twist Bioscience today announced the launch of a new line of...
Gene Therapy
PreveCeutical Clarifies Share Issuance in BioGene Arrangement Deal
Vancouver, British Columbia — November 20, 2025 — PreveCeutical Medical Inc. has issued a formal clarification regarding its earlier...
Fortress Biotech Reports Strong Q3 Growth and Pipeline Progress
MIAMI, FL — November 14, 2025 — Fortress Biotech announced its third-quarter 2025 financial results, highlighting sustained revenue growth,...
Neurogene Shows Strong Pediatric Gains in NGN-401 Rett Trial
NEW YORK—Nov. 12, 2025—Neurogene Inc. reported positive interim data from the pediatric cohort of its Phase 1/2 trial evaluating...
MavriX Bio Doses First Patient in Landmark ASCEND-AS Gene Therapy Trial
Middleton, Massachusetts – November 6, 2025 – MavriX Bio, a clinical-stage biotechnology company focused on transformative genetic medicines, announced...
AAVantgarde Secures $141 Million Series B to Advance Gene Therapies for Retinal Diseases
LONDON/MILAN, Nov. 3, 2025 — AAVantgarde Bio has raised $141 million in a Series B financing round, co-led by...
FDA Breakthrough Status Advances Rett Syndrome Gene Therapy
DALLAS, Oct. 2, 2025 — The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to TSHA-102,...
FDA Grants ODD and UK CTA Clears Gene Therapy for Stargardt
MILAN, Italy, Oct. 2, 2025 — AAVantgarde Bio announced that its investigational gene therapy AAVB-039 has received Orphan Drug...
Solid Biosciences Licenses AAV-SLB101 Capsid to Advance Gene Therapies
CHARLESTOWN, Mass., Sept. 23, 2025 — Solid Biosciences has entered a non-exclusive licensing agreement with Kinea Bio to utilize...
VectorY and ShapeTX Partner to Advance AAV5-Based CNS Therapies
AMSTERDAM, BOSTON, and SEATTLE – Sept. 18, 2025 (cGxP.wire) – VectorY Therapeutics, a biotechnology company pioneering vectorized antibody therapies...